AR020107A1 - METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS - Google Patents

METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS

Info

Publication number
AR020107A1
AR020107A1 ARP990103295A ARP990103295A AR020107A1 AR 020107 A1 AR020107 A1 AR 020107A1 AR P990103295 A ARP990103295 A AR P990103295A AR P990103295 A ARP990103295 A AR P990103295A AR 020107 A1 AR020107 A1 AR 020107A1
Authority
AR
Argentina
Prior art keywords
activity
fusion protein
full length
cell
presenilin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP990103295A
Other languages
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR020107A1 publication Critical patent/AR020107A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, que comprende las etapas: a)se cultiva una célula olínea celular que expresa dicha actividad de presenilinasa y un proteína de fusion, comprendiendo dicha proteína de fusion la presenilina 1 o presenilina 2 delongitud completa y un reportero, b)dicha célula o línea celular se incuba con un compuesto de ensayo, c)empleando el reportero,se mide la cantidad de proteínade fusion de longitud completa d)la cantidad de proteína de fusion de longitud completa medida se compara con la cantidad de proteína de fusion de longitudcompleta medida para un testigo. La sustancias identificables por un método como el descripto más arriba, que son capaces de reducir o de eliminar laactividad de la presenilinasa. Una composicion farmacéutica que comprende una sustancia como la definida más arriba y un vehículo aceptable farmacéuticamentepara la misma. El uso de una sustancia como la indicada más arriba en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas ode la enfermedad de Alzheimer o Alzheimer familia. Hasta el momento solo existían tratamientos sintomáticos de las enfermedades neurodegenerativas y, enparticular, de la enfermedad de Alzheimer. No habia ningun tratamiento modificador de la enfermedad que hiciera frente a la patología de dichas enfermedades.Tampoco existía forma terapéutica alguna para prevenir la patología debida a la deposicion de amiloidey la subsiguiente formacion de placas de amiloide.Tampoco existía forma terapéutica alguna de prevenir la muerte celular neuronal debida a fragmentos de presenilina normales o alternativos que pueden serproducir la apoptosis.Se descubrio que la supresion de la generacion de dichos fragmentos de presenilina, que pueden ser la forma biologicamente activa de laspresenilinas, y subsiguientemente el impedimento de la deposicion de amiloide,pueden realizarse reduciendo o eliminando la actividad de lapresenilinasa.Frente a estos inconvenientes del estado de la técnica, el invento propone métodos para identificar sustancias altamente específicas que son capaces deMethod for identifying a substance capable of reducing or eliminating the activity of presenilinase, which comprises the steps: a) a cell-olympic cell expressing said presenilinase activity and a fusion protein, said fusion protein comprising presenilin 1 or Presenilin 2 full length and a reporter, b) said cell or cell line is incubated with a test compound, c) using the reporter, the amount of full length fusion protein is measured d) the amount of full length fusion protein measurement is compared with the amount of full length fusion protein measured for a control. The substances identifiable by a method like the one described above, which are capable of reducing or eliminating the activity of presenilinase. A pharmaceutical composition comprising a substance as defined above and a pharmaceutically acceptable carrier for it. The use of a substance such as that indicated above in the preparation of a drug for the treatment of neurodegenerative diseases or of the Alzheimer's disease or Alzheimer's family. So far there were only symptomatic treatments of neurodegenerative diseases and, in particular, of Alzheimer's disease. There was no disease-modifying treatment to cope with the pathology of these diseases. There was also no therapeutic way to prevent the pathology due to the deposition of amyloid and the subsequent formation of amyloid plaques. There was also no therapeutic way to prevent death. neuronal cell due to normal or alternative presenilin fragments that may be producing apoptosis. It was discovered that the suppression of the generation of said presenilin fragments, which may be the biologically active form of laspresenilines, and subsequently the impediment of amyloid deposition, they can be carried out by reducing or eliminating the activity of lapresenilinase. In the face of these drawbacks of the prior art, the invention proposes methods for identifying highly specific substances that are capable of

ARP990103295A 1998-07-09 1999-07-07 METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS Pending AR020107A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98112688 1998-07-09

Publications (1)

Publication Number Publication Date
AR020107A1 true AR020107A1 (en) 2002-04-10

Family

ID=8232244

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103295A Pending AR020107A1 (en) 1998-07-09 1999-07-07 METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS

Country Status (7)

Country Link
EP (1) EP1095279A1 (en)
JP (1) JP2002520031A (en)
AR (1) AR020107A1 (en)
AU (1) AU5034099A (en)
CA (1) CA2332344A1 (en)
UY (1) UY25604A1 (en)
WO (1) WO2000003248A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000161A1 (en) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard
EP1305634A2 (en) * 2000-04-03 2003-05-02 Bristol-Myers Squibb Company Fluorescence assay for gamma-secretase activity and inhibitors
JP2021525245A (en) * 2018-05-22 2021-09-24 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Gene therapy for Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
GB9608657D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel treatment
CA2288227A1 (en) * 1997-04-24 1998-10-29 The General Hospital Corporation A purified 20 kda presenilin 2 c-terminal fragment and methods of screening for compounds that inhibit proteolysis of presenilin 2

Also Published As

Publication number Publication date
UY25604A1 (en) 2000-02-23
AU5034099A (en) 2000-02-01
WO2000003248A1 (en) 2000-01-20
EP1095279A1 (en) 2001-05-02
CA2332344A1 (en) 2000-01-20
JP2002520031A (en) 2002-07-09

Similar Documents

Publication Publication Date Title
Yamamoto et al. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation
Bevelander et al. The effect of the administration of tetracycline on the development of teeth
Dong et al. Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease
KR102436886B1 (en) Neurodegenerative disorders
BRPI0408256A (en) compound, methods of treating a human or animal by limiting cell replication, suffering from cancer, suffering from a neoplastic disease, and suffering from proliferative diseases, use of a compound, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof
MXPA02012164A (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
Shigyo et al. Extracellular vimentin is a novel axonal growth facilitator for functional recovery in spinal cord-injured mice
DE60126980D1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES
Wang et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation
BRPI0409427A (en) compound, use thereof, pharmaceutical composition, method of treating a human suffering from a hyperproliferative disease, and process for the preparation of a compound or a pharmaceutically acceptable salt, ester or prodrug thereof
JP2022511785A (en) Compositions and Methods for Treating Dementia
CZ300549B6 (en) Pharmaceutical composition containing cilobradine
JPH03145419A (en) Drug of preventing ultraviolet light aging
EP1707202A1 (en) Organic compounds
Pan et al. Novel Caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window
AR020107A1 (en) METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS
KR101173677B1 (en) Pharmaceutical composition for preventing or treating diseases associated with beta amyloid accumulation containing EPPS as an active ingredient
JP4800194B2 (en) Use of kahalalide compounds for the manufacture of a treatment for psoriasis
DE112018005145T5 (en) INHIBITION OF AMINOACYLASE 3 (AA3) IN TREATMENT OF CANCER
KR20220076375A (en) A novel pharmaceutical composition for treating neurodegenerative disease
WO2023047810A1 (en) Regulator for primary cilia of immune-related cells and use thereof
CN104292126B (en) Naphthalene derivatives and the application on medicine thereof
AR005724A1 (en) BIOLOGICALLY ACTIVE UREID DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS
ITUB20159141A1 (en) TREATMENT OF CEREBRAL TUMOR
Zubachyk et al. Biopharmaceutical evaluation of new semi-solid preparation with thiotriazoline and chloramphenicol